Form D · Biotechnology
Cloverleaf Bio, Inc.
New Haven, CT · CIK 0002153574
Offering snapshot reported Sep 9, 2026 · SEC filing
- Reported sold
- $14.8M Offering amount: $29.6M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 24, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 9, 2026 | Initial | $14,799,988 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-596761
Source: Form D, filed Sep 9, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Austin Draycott | Director, Executive |
| Dima Kuzmin | Director |
| Cole Lewis | Executive |
| Matthias Samwer | Director |
| Christina Vorvis | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 College Street, #210
New Haven, CT, 06510
Phone: 347-596-9754
New Haven, CT, 06510
Phone: 347-596-9754